Legal & General Group Plc Invests $7.15 Million in ACADIA Pharmaceuticals Inc. $ACAD

Posted by Brian Himes on Sep 3rd, 2026

Legal & General Group Plc bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 282,510 shares of the biopharmaceutical company’s stock, valued at approximately $7,148,000.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in ACADIA Pharmaceuticals by 74.4% in the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock valued at $1,338,000 after acquiring an additional 34,352 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 3.8% during the 1st quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock valued at $1,124,000 after purchasing an additional 2,492 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ACADIA Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 6,303 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of ACADIA Pharmaceuticals during the first quarter valued at about $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of ACADIA Pharmaceuticals by 14.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock valued at $4,170,000 after purchasing an additional 31,931 shares in the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Trading Up 0.1%

ACADIA Pharmaceuticals stock opened at $28.93 on Thursday. The firm has a 50-day moving average price of $27.16 and a 200-day moving average price of $23.81. The firm has a market capitalization of $4.98 billion, a PE ratio of 13.03, a price-to-earnings-growth ratio of 21.54 and a beta of 0.86. ACADIA Pharmaceuticals Inc. has a 12-month low of $19.69 and a 12-month high of $30.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. The firm had revenue of $308.00 million during the quarter, compared to analysts’ expectations of $296.55 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The firm’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.16 EPS. As a group, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ACAD shares. Deutsche Bank Aktiengesellschaft lifted their target price on ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Citizens Jmp raised their price target on ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the company a “market outperform” rating in a report on Wednesday, August 5th. Morgan Stanley lifted their price objective on ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 25th. Weiss Ratings raised ACADIA Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, August 12th. Finally, UBS Group increased their target price on ACADIA Pharmaceuticals from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.36.

View Our Latest Stock Report on ACAD

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 14,292 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $29.22, for a total value of $417,612.24. Following the sale, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,981,934.16. This represents a 17.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the sale, the executive vice president directly owned 18,994 shares of the company’s stock, valued at $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,699 shares of company stock valued at $1,019,894 in the last 90 days. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.